Chernett Jorey reported an Exagen share purchase on Form 4

What did Chernett Jorey report?

The SEC Form 4 reports an open-market purchase of 14,000 Exagen shares at $7.46 each, about $104K in total. Chernett Jorey is identified as a 10% owner.

After the purchase, the reported holding was 2,618,540 shares. The filing describes this as an increase of about 0.5% over the estimated holding before the purchase.

When was the purchase made and reported?

The transaction date was Oct 19, 2026. Chernett Jorey filed the Form 4 on Oct 20, 2026, 1 day later.

The purchase came 76 days after Exagen's results announcement on Aug 4, 2026, reported under 8-K Item 2.02.

How does the purchase compare with earlier filings?

In the 365 days to Oct 20, 2026, OQRO holds 14 other open-market purchases by Chernett Jorey, about $4.81M in total, and 0 of them were at Exagen. OQRO also holds 1 open-market sale by Chernett Jorey in that period, about $321. OQRO holds no earlier open-market purchase by this person in 23 months of their filings.

Of Chernett Jorey's 23 disclosed purchases since Oct 20, 2025, 21 have had 90 days since they were reported. Measured from the first close after each report, the median result was 52.1 points above the S&P 500 (SPY), with 76% ahead of it. These figures start at the report, treat every purchase as equal, and describe the past only; they rest on a small sample.

No other open-market purchases at Exagen are on record in the 455 days to Oct 20, 2026. Comparisons use only the filings OQRO holds.

What else is on record around Exagen?

Insiders at Exagen also filed 2 open-market sales, about $419K, in those 90 days. FINRA short interest for XGN on the settlement date of Sep 30, 2026 was 704,634 shares, -11.96% on the previous report, or about 2.46 days of average volume.

In 13F filings for the quarter ended Jun 30, 2026, Flputnam Investment Management Co had the largest position that grew, marked as a new position. The largest positions that shrank were Silvercrest Asset Management Group LLC, reduced by 23,109 shares, and Kennedy Capital Management LLC, reduced by 8,612 shares. A 13F is a quarter-end snapshot with no trade date.

What happened to XGN's share price around the purchase?

XGN closed at $7.43 on Oct 19, 2026, the last session on or before the transaction date. From Sep 21, 2026 to Oct 19, 2026, the close moved from $8.62 to $7.43, a change of −13.8%.

These price moves are context only. The filing does not explain them, and other news can move a price. See Exagen on OQRO for the public-filings context OQRO holds.

What this does not tell you?

A Form 4 reports a transaction but does not say why it was made. Some purchases and sales follow trading windows or pre-arranged plans, and OQRO notes a plan only when a filing footnote says so. General background is that many companies let insiders trade only in a window that opens after results, and a sale can also follow an option exercise or a tax bill; the Form 4 does not say which circumstances apply here.

This describes public filings and is not investment advice.